口服Limosilactobacillus fermentum ACA-DC 179可通过对小鼠肠道微生物群的调节减轻非脂蛋白E缺乏的小鼠的动脉样硬化进展
I Ferrocino1, G Zoumpopoulou2, D Lali2,3
1Department of Agricultural, Forest and Food Science, University of Turin, Grugliasco, Italy.
Beneficial microbes
|May 1, 2025
概括
乳酸菌发酵 ACA-DC 179 益生菌的使用显著降低了小鼠动脉样硬化进展. 这种有益的效果与肠道微生物群组成的有利变化和降低的甘油三水平有关.
科学领域:
- 微生物学 微生物学
- 心血管科学 心血管科学
- 胃肠病学 胃肠病学
背景情况:
- 肠道微生物群失生症越来越多地与动脉样硬化发展有关.
- 益生菌正在被探索作为调节肠道微生物群和减轻心血管疾病风险的战略.
研究的目的:
- 为了研究Limosilactobacillus fermentum ACA-DC 179对阿波利波蛋白E缺陷 (ApoE-/-) 的小鼠动脉样硬化进展的影响.
- 分析益生菌治疗对肠道微生物群组成和血清生物化学标记物的影响.
主要方法:
- ApoE-/-小鼠接受了低剂量或高剂量的L. fermentum ACA-DC 179治疗,持续了8周.
- 肠道微生物群使用古典微生物学和元taxonomic方法进行了分析.
- 评估了血清生化标志物和动脉样硬化病变大小.
主要成果:
- 高剂量的L. fermentum ACA-DC 179显著增加了乳杆菌种类. 在雄性小鼠便中.
- 益生菌治疗改变了肠道微生物群,减少了Lachnoclostridium和增加了Erysipelatoclostridium.
- 三甘油降低,动脉样硬化病变在接受高剂量的雄性和雌性小鼠中显著减弱.
结论:
- 在ApoE-/-小鼠中,L. fermentum ACA-DC 179的使用减轻了动脉样硬化的发展.
- 改变肠道微生物群的组成似乎在观察到的心脏保护作用中起着重要作用.
- 需要进一步的研究来阐明L. fermentum ACA-DC 179的益处的潜在机制.
相关概念视频
01:21Drugs for Treatment of Constipation-Predominant IBS
109
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
109
01:50What is Monogastric Digestion?
69.6K
The human body contains a monogastric digestive system. In a monogastric digestive system, the stomach only contains one chamber in which it digests food. Several other animal species also have monogastric digestive systems, including pigs, horses, dogs, and birds. This chapter, however, focuses on the human digestive system.
69.6K